JP2024506709A5 - - Google Patents

Info

Publication number
JP2024506709A5
JP2024506709A5 JP2023549575A JP2023549575A JP2024506709A5 JP 2024506709 A5 JP2024506709 A5 JP 2024506709A5 JP 2023549575 A JP2023549575 A JP 2023549575A JP 2023549575 A JP2023549575 A JP 2023549575A JP 2024506709 A5 JP2024506709 A5 JP 2024506709A5
Authority
JP
Japan
Prior art keywords
composition according
aso
oligonucleotide
bases
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506709A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016842 external-priority patent/WO2022178160A1/en
Publication of JP2024506709A publication Critical patent/JP2024506709A/ja
Publication of JP2024506709A5 publication Critical patent/JP2024506709A5/ja
Pending legal-status Critical Current

Links

JP2023549575A 2021-02-17 2022-02-17 Ube3aアンチセンス治療剤 Pending JP2024506709A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150188P 2021-02-17 2021-02-17
US63/150,188 2021-02-17
PCT/US2022/016842 WO2022178160A1 (en) 2021-02-17 2022-02-17 Ube3a antisense therapeutics

Publications (2)

Publication Number Publication Date
JP2024506709A JP2024506709A (ja) 2024-02-14
JP2024506709A5 true JP2024506709A5 (cg-RX-API-DMAC10.html) 2025-02-25

Family

ID=82802019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549575A Pending JP2024506709A (ja) 2021-02-17 2022-02-17 Ube3aアンチセンス治療剤

Country Status (5)

Country Link
US (1) US20220259601A1 (cg-RX-API-DMAC10.html)
EP (1) EP4294925A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024506709A (cg-RX-API-DMAC10.html)
CA (1) CA3211396A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022178160A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024397279A1 (en) 2023-12-13 2026-07-02 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with ube3a overexpression
WO2025128816A1 (en) * 2023-12-13 2025-06-19 Kicho Inc. Methods of modulating expression of ube3a gene
AR134762A1 (es) * 2023-12-21 2026-04-01 Hoffmann La Roche Oligonucleótido antisentido
WO2026049020A1 (ja) * 2024-09-02 2026-03-05 学校法人関西学院 修飾オリゴヌクレオチド又はその塩

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858987A (en) * 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
US6617442B1 (en) * 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
EP2410053B2 (en) * 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
PE20090064A1 (es) * 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
US20150322428A1 (en) * 2012-06-18 2015-11-12 Isis Pharmaceuticals, Inc. Compounds and methods for improved cellular uptake of antisense compounds
CA2975525A1 (en) * 2015-02-04 2016-08-11 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
EP3911957A1 (en) * 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG E3 ubiquitin ligase (ube3a) protein targets
TW202536179A (zh) * 2019-03-29 2025-09-16 美商Ionis製藥公司 用於調節ube3a-ats之化合物及方法

Similar Documents

Publication Publication Date Title
CN105838714B (zh) 反义分子和治疗疾病的方法
Mercatante et al. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases
KR20230043912A (ko) Lpa 발현을 저해하기 위한 조성물 및 방법
US20140066491A1 (en) Chemical modification motifs for mirna inhibitors and mimetics
AU2010210605B2 (en) Dual targeting of miR-208 and miR-499 in the treatment of cardiac disorders
JP2012147790A (ja) エキソンスキッピングを誘発する為の手段及び方法
Sharma et al. The therapeutic potential of antisense oligonucleotides
US9163235B2 (en) Inhibitors of the miR-15 family of micro-RNAs
NZ572199A (en) Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly or abnormally expressed gene
JP2009508527A (ja) グルココルチコイド受容体発現の調節
AU2019234917B2 (en) Inhibitors of micro-RNA 22
JP2009535039A5 (cg-RX-API-DMAC10.html)
CA3211396A1 (en) Ube3a antisense therapeutics
JP2025072578A (ja) B型肝炎ウイルス感染症を処置するためのsept9阻害剤の使用
JP2026500220A (ja) 高度rna標的化(arnatar)
JP2025166835A (ja) B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用
JP2024073525A5 (cg-RX-API-DMAC10.html)
JP2023538630A (ja) B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用
JP2024515240A5 (cg-RX-API-DMAC10.html)
CN114867856A (zh) Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
JP2021513851A5 (cg-RX-API-DMAC10.html)
CN114829601A (zh) Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
US20230193269A1 (en) Oligonucleotides for splice modulation of card9
CN115551519A (zh) 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
JP2024518788A5 (cg-RX-API-DMAC10.html)